BAK Autoactivation in Hematological Malignancies
Description: PROJECT NARRATIVE Members of the BCL2 protein family regulate life/death decisions by modulating mitochondrial outer membrane permeability. Our previous results have demonstrated that the pro-apoptotic family member BAK is constitutively activated in a subset of acute myeloid leukemia (AML) samples as well as leukemia and lymphoma cell lines, priming them to respond to certain treatments. With an eye toward improving AML therapy, this project focuses on i) understanding the cellular and biochemical bases for this constitutive BAK activation and ii) determining the implications of constitutive BAK activation for respose to AML treatment in the clinic, using as an example the response to a novel regimen of targeted agents that is currently being developed for use in AML.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2020-07-01
End date: 2025-06-30
Investigator: SCOTT H KAUFMANN (lead)
Institutions: Mayo Clinic, MAYO CLINIC ROCHESTER
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 7
Funder award ID: R01CA225996
OpenAlex ID: G1040924669
